United States biotechnology companies are currently engaged in an industry-wide regeneration. In February 2023, RBC Capital Markets presented an intensive biotech industry market analysis that addressed the factors behind the sector’s recent slowdowns. In the analysts’ view, “expanded numbers of unproven early-stage recent IPO names” had led to regulatory and clinical trial difficulties.
Beginning in mid-2022, the biotech industry began to turn around. Biotech-focused venture capital firms, such as Dr. Leen Kawas’ Propel Bio Partners, continue to recognize quality candidates.
Equally importantly, the biotech industry’s commercial results continue to be strong. These encouraging outcomes demonstrate that the sector is relatively unaffected by inflationary pressures and recession worries.